INNV-32. LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY CONSOLIDATION STEREOTACTIC RADIOSURGERY (LITT-CSRS) IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASIS

Abstract INTRODUCTION The efficacy and safety of laser interstitial thermal therapy followed by consolidation radiosurgery (LITT-cSRS) was previously studied in brain metastasis that recurs locally after initial radiosurgery (BMRS). Here, we characterize the clinical outcome of LITT-cSRS in patients with newly diagnosed brain metastasis. METHODS Between 2017 and 2023, ten consecutive cancer patients with newly diagnosed brain mass of unclear etiology who underwent stereotactic needle biopsy (SNB) and LITT in the same setting followed by consolidation SRS (cSRS) with > 6 months follow-up were identified retrospectively. Clinical and imaging outcomes were collected. RESULTS The histology of the BM were: breast cancer (n=3), melanoma (n=3), non-cell cell lung cancer (n=3), colon (n=1). There were no wound or procedural complications. All patients were discharged home, with a median one-day hospital stay (range: 1-2 days). All patients were off corticosteroid therapy by the one-month follow-up. cSRS were carried out 12-27 days (median of 19 days) after SNB+LITT. There were no subsequent emergency room presentation, 30-day or 90-day re-admission. The Karnofsky Performance Score (KPS) remains stable or improved at the 3 months-follow-up. With a median follow-up of 416 days (13.8 mo; range: 199-1,096 days), there was one local recurrence at 384 days (12.8 mo) post-LITT-cSRS. Of note, this is the only patient who underwent incomplete ablation with LITT and the location of the recurrence corresponded to the residual tumor that was not treated with LITT. With exception of this patient with local recurrence, all patients showed decreased FLAIR volume surrounding the LITT-cSRS treated BMRS by the six-month follow-up. CONCLUSIONS To our awareness, this case series represent the first to describe LITT-cSRS in the setting of newly diagnosed BM. The results presented here provide pilot data to support the safety and efficacy of LITT-cSRS and lay the foundation for future studies.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2024-11-01
DOI
https://doi.org/10.1093/neuonc/noae165.0694
Primary Topic
Brain Metastases and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

INNV-32. LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY CONSOLIDATION STEREOTACTIC RADIOSURGERY (LITT-CSRS) IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASIS

Rajiv Dharnipragada, Margaret Reynolds, Clark C. Chen, Rena Shah et al.
Neuro-Oncology
Brain Metastases and Treatment
article

INNV-32. LASER INTERSTITIAL THERMAL THERAPY FOLLOWED BY CONSOLIDATION STEREOTACTIC RADIOSURGERY (LITT-CSRS) IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASIS

Rajiv Dharnipragada, Margaret Reynolds, Clark C. Chen, Rena Shah, Kathryn E. Dusenbery
article en

Abstract

Abstract INTRODUCTION The efficacy and safety of laser interstitial thermal therapy followed by consolidation radiosurgery (LITT-cSRS) was previously studied in brain metastasis that recurs locally after initial radiosurgery (BMRS). Here, we characterize the clinical outcome of LITT-cSRS in patients with newly diagnosed brain metastasis. METHODS Between 2017 and 2023, ten consecutive cancer patients with newly diagnosed brain mass of unclear etiology who underwent stereotactic needle biopsy (SNB) and LITT in the same setting followed by consolidation SRS (cSRS) with > 6 months follow-up were identified retrospectively. Clinical and imaging outcomes were collected. RESULTS The histology of the BM were: breast cancer (n=3), melanoma (n=3), non-cell cell lung cancer (n=3), colon (n=1). There were no wound or procedural complications. All patients were discharged home, with a median one-day hospital stay (range: 1-2 days). All patients were off corticosteroid therapy by the one-month follow-up. cSRS were carried out 12-27 days (median of 19 days) after SNB+LITT. There were no subsequent emergency room presentation, 30-day or 90-day re-admission. The Karnofsky Performance Score (KPS) remains stable or improved at the 3 months-follow-up. With a median follow-up of 416 days (13.8 mo; range: 199-1,096 days), there was one local recurrence at 384 days (12.8 mo) post-LITT-cSRS. Of note, this is the only patient who underwent incomplete ablation with LITT and the location of the recurrence corresponded to the residual tumor that was not treated with LITT. With exception of this patient with local recurrence, all patients showed decreased FLAIR volume surrounding the LITT-cSRS treated BMRS by the six-month follow-up. CONCLUSIONS To our awareness, this case series represent the first to describe LITT-cSRS in the setting of newly diagnosed BM. The results presented here provide pilot data to support the safety and efficacy of LITT-cSRS and lay the foundation for future studies.

Neuro-OncologyVol. 26(Supplement_8)
University of Minnesota (US), Brown University (US), HealthPartners (US)
Good health and well-being
Openalex Percentile: Top 62%
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.